April 19, 2016
AbbVie G.K. said on April 18 that it has commenced a PIIb/III clinical study of its once daily oral selective JAK1 inhibitor ABT-494 in Japan for the treatment of rheumatoid arthritis (RA). The study will enroll moderate to severe active...read more